Publication:
The Effects of Protocadherin 8 and WWOX in Prostate Adenocarcinoma

dc.authorscopusid57210376597
dc.authorscopusid11739076200
dc.authorscopusid23988464900
dc.authorscopusid57192013600
dc.contributor.authorÇelik, M.A.
dc.contributor.authorErdem, H.
dc.contributor.authorÇankaya, S.
dc.contributor.authorKasko Arici, Y.K.
dc.date.accessioned2025-12-11T00:30:17Z
dc.date.issued2022
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Çelik] Mürüvvet Akçay, Department of Pathology, Ordu Üniversitesi, Ordu, Turkey; [Erdem] Havva, Department of Pathology, Ordu Üniversitesi, Ordu, Turkey; [Çankaya] Soner, Department of Management, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kasko Arici] Yeliz, Department of Biostatistics and Medical Informatics, Ordu Üniversitesi, Ordu, Turkeyen_US
dc.description.abstractObjective: The protocadherin 8 (PCDH8) gene, located on chromosome 13q14.3 encodes an integral membrane protein. WWOX (fragile site FRA16D oxido-reductase) is a tumor suppressor gene located in region 16q23.324.1. The aim of this study was to investigate the staining pattern of protocadherin 8 and WWOX in adenomatous hyperplasia and prostate adenocarcinoma. Methods: Seventy adenomatous hyperplasia and 70 prostate adenocarcinoma preparations stored at the pathology department from 2013–2016 were retrospectively analyzed. Samples immunohistochemically stained with WWOX or protocadherin 8 were evaluated by two pathologists under a light microscope. After pathological investigation of the samples, the expression of WWOX and protocadherin 8 was scored. WWOX and PCDH8 expression was assessed semi-quantitatively according to staining intensity scored as none, mild, moderate, and strong (0 to 3+). For analysis of the data, the mild, moderate and strong staining scores were combined (as positive) and the data were classified as negative or positive. Differences in the WWOX or protocadherin 8 staining results between adenomatous hyperplasia and prostate adenocarcinoma cases were examined using a two-way chi-square test and binary logistic regression analysis. Result: Statistical analysis showed that WWOX expression was higher in adenomatous hyperplasia than in prostate adenocarcinomas. This difference was statistically significant (p = 0.035). There was no difference in PCDH8 expression between adenomatous hyperplasia and prostate adenocarcinoma samples (p = 0.217). Conclusion: In this study, the expression of WWOX decreased and the expression of PCDH8 remained unchanged in PCa cases. In terms of prognostic significance, it can be concluded that WWOX is a good prognostic parameter, while PCDH8 was an ineffective prognostic marker. In addition, the investigation of protocadherin 8 in larger series may provide more meaningful results. © 2022 The Author(s). Published by IMR Press.en_US
dc.identifier.doi10.31083/J.JOMH1804102
dc.identifier.issn1875-6867
dc.identifier.issn1875-6859
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85130190249
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.31083/J.JOMH1804102
dc.identifier.urihttps://hdl.handle.net/20.500.12712/36894
dc.identifier.volume18en_US
dc.identifier.wosqualityQ4
dc.language.isoenen_US
dc.publisherIMR Press Limiteden_US
dc.relation.ispartofJournal of Men's Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLogistic Regression Analysisen_US
dc.subjectProstateen_US
dc.subjectProtocadherin 8en_US
dc.subjectWWOXen_US
dc.titleThe Effects of Protocadherin 8 and WWOX in Prostate Adenocarcinomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files